Evidence map›Paper›PMID 41918502›Full record

ReviewThe Yale journal of biology and medicine2026

Tau Pathology in Chronic Traumatic Encephalopathy: Mechanisms and Diagnostic Advances.

Joel Chesters

Abstract readReview
In one paragraph

Review in The Yale journal of biology and medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Joel ChestersUniversity of Oxford, St. Catherine's College, Oxford, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic Traumatic Encephalopathy (CTE) is a progressive neurodegenerative tauopathy associated with repetitive head impacts (RHI), yet it remains diagnosable only at post-mortem. Tau, a microtubule-associated protein, normally stabilizes neuronal microtubules and regulates cytoskeletal dynamics. Mechanical strain from RHI is thought to disrupt calcium homeostasis and kinase-phosphatase balance, driving hyperphosphorylation and phosphorylated-tau (p-tau) formation. This results in detachment from microtubules and subsequent p-tau aggregation. These mechanically-induced biochemical changes produce CTE's characteristic lesion: perivascular p-tau deposition in the depths of cortical sulci, reflecting the non-uniform mechanical loading experienced by brain tissue following head impacts. Advances in molecular neuropathology have revealed that CTE tau filaments adopt a unique conformational fold, and that early tau species may contribute to neurotoxicity. Despite this growing understanding, antemortem diagnosis remains challenging. Structural MRI demonstrates frontotemporal atrophy and white-matter abnormalities in impact-exposed individuals, but these findings lack disease specificity. Tau-PET tracers developed for Alzheimer's disease (AD) show limited affinity for the distinct CTE tau fold, while fluid biomarkers variably reflect cumulative exposure but cannot yet discriminate CTE from other tauopathies. Future progress will depend on mechanistically informed diagnostic tools, including conformation-specific biomarkers and PET radiotracers tailored to CTE-specific tau. Multimodal approaches integrating neuroimaging, molecular profiling, exposure metrics, and computational modelling will be essential for early detection, disease monitoring, and informed public health policy around repetitive head impacts.

Indexed as

Chronic Traumatic EncephalopathyTauopathiestau ProteinsAnimalsBiomarkersHumansBiomarkerstau ProteinsChronic Traumatic EncephalopathyConcussionCTENeurodegenerationRepetitive Head Impacts

Identifiers

PMID41918502
PMCPMC13023417

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.